1. Semaglutide may be linked to a lower risk of stroke in adult patients with type 2 diabetes.
2. Patients treated with semaglutide showed greater weight loss and better glycemic control than those treated with empagliflozin.
3. The study had limitations due to its observational design and reliance on prescription records.
4. The benefit for semaglutide was most evident in patients younger than 65 years and those with baseline HbA1c below 7%.
5. Geographic differences in the benefit of semaglutide were observed, with southwestern Pennsylvania showing the most evident benefit. 

Source: Annals of Internal Medicine